 |
 |
LE PONT-DE-CLAIX, France and BURGDORF, Switzerland, October 23, 2024 / Biotech Newswire / -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced a strategic collaboration with Ypsomed, a leading developer of injection systems, to advance self-injection solutions for high-viscosity biologic drugs. In a joint project, Ypsomed and BD have pre-assessed and streamlined integration of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe with Ypsomed’s YpsoMate® 2.25 autoinjector platform, addressing current limitations by enabling the delivery of higher viscosity (>15cP) biologic drugs in an autoinjector format.
Designed to flow beyond limits
The BD Neopak™ XtraFlow™ Glass Prefillable Syringe is BD’s latest portfolio addition, featuring a shorter, 8-millimeter needle length, and thinner wall cannula to optimize subcutaneous delivery of higher viscosity drug profiles. This improvement allows pharmaceutical developers to break design barriers, enhancing flow and usability beyond today’s limits versus a standard half-inch needle (1,2*) This solution is a part of the BD Neopak™ Glass Prefillable Syringe Platform, which is designed to address key development needs for biologic drugs.
To support this innovation, Ypsomed is expanding its YpsoMate® 2.25 two-step autoinjector platform to accommodate the new syringe format. This includes adapting parts of the autoinjector for the shorter needle, qualifying tooling and assembly, and performing extensive technical testing to ensure reliability. The YpsoMate autoinjector device is handled in two steps: simply remove the cap and push on skin, designed so that people with impaired grip or vision can administer their medication easily and safely.
Supporting our pharmaceutical partners to de-risk and accelerate combination product development
“We are excited to welcome the first pharmaceutical customers to experience the benefits of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe with the YpsoMate® 2.25 autoinjector,” said Ulrike Bauer, Chief Business Officer of Ypsomed Delivery Systems. “This collaboration underscores our commitment to enhancing patient care through innovative drug delivery solutions.”
“Cross-supplier collaborations are vital in today’s pharmaceutical ecosystem,” said Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems. “These partnerships can help drive innovation and ensure that systems work by design and over lifecycles, allowing our pharmaceutical partners to get life-saving therapies to patients faster.”
BD and Ypsomed are key leaders in drug delivery, enabling the administration of chronic condition therapeutics such as GLP-1s, antibodies, and other next generation formulations. Combining BD’s robust syringe platform technology with Ypsomed’s leading autoinjector platform, this collaboration leverages shared expertise to deliver reliable device systems.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
Contacts
BD
Media:
Fallon McLoughlin
Director, Public Relations
+1 201.258.0361
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors:
Adam Reiffe
Sr. Director, Investor Relations
+1 201.847.6927
This email address is being protected from spambots. You need JavaScript enabled to view it.
Ypsomed Holding AG
Media & Investor Relations:
Susanne Köhler
Head of Public Relations
+41 34 424 47 32
This email address is being protected from spambots. You need JavaScript enabled to view it.
References
1. Injection time and ejection force calculation [internal study], Le Pont-de-Claix, France; Becton, Dickinson and Company, 2021
2. Pager et al. (2020), “User experience for manual injection of 2 mL viscous solutions is enhanced by a new prefillable syringe with staked 8 mm ultra-thin wall needle”, Expert Opinion on Drug Delivery, https://doi.org/10.1080/17425247.2020.1796630
*When compared to 12.7 mm special thin wall needle
BD, the BD Logo, Neopak, and XtraFlow are trademarks of Becton, Dickinson and Company or its affiliates. © 2024 BD. All rights reserved.
YpsoMate is a registered trademark of Ypsomed AG
Keywords: Intersectoral Collaboration; Syringes; Viscosity; Equipment and Supplies, Hospital; Drug Delivery Systems; Syringes; Glass; Injections; Subcutaneous Tissue; Technology; Hospitals; Equipment Design; Pharmaceutical Preparations; Biological Therapy; France; Switzerland; Ypsomed; Becton, Dickinson and Company; BD; self-injection systems; high-viscosity biologics; strategic collaboration; BD Neopak™ XtraFlow™ Glass Prefillable Syringe; YpsoMate® 2.25 autoinjector; biologic drugs; subcutaneous delivery; drug delivery; two-step autoinjector; combination product development; drug delivery solutions; syringe platform technology; autoinjector platform
Source: Biotech Newswire